Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists

被引:23
作者
Alhiary, Rasha [1 ,2 ,3 ]
Kesselheim, Aaron S. [2 ,3 ]
Gabriele, Sarah [2 ,3 ]
Beall, Reed F. [4 ]
Tu, S. Sean [5 ]
Feldman, William B. [2 ,3 ,6 ]
机构
[1] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
[2] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law, Boston, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada
[5] West Virginia Univ, Coll Law, Morgantown, WV USA
[6] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2023年 / 330卷 / 07期
关键词
MARKET EXCLUSIVITY; PRESCRIPTION DRUGS; PRODUCTS;
D O I
10.1001/jama.2023.13872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive. OBJECTIVE To analyze how manufacturers of brand-name GLP-1 receptor agonists have used the patent and regulatory systems to extend periods of market exclusivity. EVIDENCE REVIEW The annual US Food and Drug Administration's (FDA) Approved Drug Products With Therapeutic Equivalence Evaluations was used to identify GLP-1 receptor agonists approved from 2005 to 2021 and to record patents and nonpatent statutory exclusivities listed for each product. Google Patents was used to extract additional data on patents, including whether each was obtained on the delivery device or another aspect of the product. The primary outcome was the duration of expected protection from generic competition, defined as the time elapsed from FDA approval until expiration of the last-to-expire patent or regulatory exclusivity. FINDINGS On the 10 GLP-1 receptor agonists included in the cohort, drug manufacturers listed with the FDA a median of 19.5 patents (IQR, 9.0-25.8) per product, including a median of 17 patents (IQR, 8.3-22.8) filed before FDA approval and 1.5 (IQR, 0-2.8) filed after FDA approval. Fifty-four percent of all patents listed on GLP-1 receptor agonists were on the delivery devices rather than active ingredients. Manufacturers augmented patent protection with a median of 2 regulatory exclusivities (IQR, 0-3) obtained at approval and 1 (IQR, 0.3-4.3) added after approval. The median total duration of expected protection after FDA approval, when accounting for both preapproval and postapproval patents and regulatory exclusivities, was 18.3 years (IQR, 16.0-19.4). No generic firm has successfully challenged patents on GLP-1 receptor agonists to gain FDA approval. CONCLUSIONS AND RELEVANCE Patent and regulatory reform is needed to ensure timely generic entry of GLP-1 receptor agonists to the market.
引用
收藏
页码:650 / 657
页数:8
相关论文
共 32 条
  • [1] 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022
    American Diabetes Association Professional Practice Committee*
    [J]. DIABETES CARE, 2022, 45 : S113 - S124
  • [2] [Anonymous], 2005, DRUG APPR PACK BYETT
  • [3] [Anonymous], 2020, Frequently Asked Questions On Patents And Exclusivity
  • [4] Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead
    Baig, Khrysta
    Dusetzina, Stacie B.
    Kim, David D.
    Leech, Ashley A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (11) : 961 - 963
  • [5] Patent term restoration for top-selling drugs in the United States
    Beall, Reed F.
    Darrow, Jonathan J.
    Kesselheim, Aaron S.
    [J]. DRUG DISCOVERY TODAY, 2019, 24 (01) : 20 - 25
  • [6] Tertiary patenting on drug-device combination products in the United States
    Beall, Reed F.
    Kesselheim, Aaron S.
    [J]. NATURE BIOTECHNOLOGY, 2018, 36 (02) : 142 - 146
  • [7] Improving the quality of US drug patents through international awareness
    Bloomfield, Doni
    Lu, Zhigang
    Kesselheim, Aaron S.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2022, 377 : e068172
  • [8] Centers for Medicare & Medicaid Services, MED PRIC NEG PROGR
  • [9] Congressional Research Service, 2021, R46679 CRS
  • [10] Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023
    ElSayed, Nuha A.
    Aleppo, Grazia
    Aroda, Vanita R.
    Bannuru, Raveendhara R.
    Brown, Florence M.
    Bruemmer, Dennis
    Collins, Billy S.
    Hilliard, Marisa E.
    Isaacs, Diana
    Johnson, Eric L.
    Kahan, Scott
    Khunti, Kamlesh
    Leon, Jose
    Lyons, Sarah K.
    Perry, Mary Lou
    Prahalad, Priya
    Pratley, Richard E.
    Seley, Jane Jeffrie
    Stanton, Robert C.
    Gabbay, Robert A.
    [J]. DIABETES CARE, 2023, 46 : S140 - S157